AD PHARMA
ActiveActs, filings and financial milestones
Deadline for the 2026 accounts:
2026
29-10
Gazette deed
Appointment: Asmae ABAIDA (director)3 points ▸
Gazette deed
Appointment: Asmae ABAIDA (director)
3 points ▸
- General meeting, 01-10-2026
- Director appointment, Asmae ABAIDA (director)
- Board meeting, 01-10-2026
02-07
abbreviated format · 29 days before the deadline
2025
31-12
Financial
Highest result from 2020 to 2025net €88,132 ▲206%
The operating result of €141,828 and the net result of €88,132 are both a record.
31-12
Financial
Equity above €100,000equity €118,742 ▲288%
After 4 profitable years in a row, equity reaches €118,742.
20-08
full format · 20 days late
2024
21-08
full format · 21 days late
2023
29-06
full format · 32 days before the deadline
2022
31-12
Financial
Back to profitnet €62,439
The net result is €62,439, after one loss-making year.
30-06
full format · 31 days before the deadline
2021
31-12
Financial
Weakest financial yearnet -€12,117
The net result drops to -€12,117, the lowest from 2020 to 2025. It recovers the following year.
16-06
micro format · 45 days before the deadline
2019
30-10
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank